What are
GENERIC MEDICINES
Generics are drugs that contain the same active ingredients, in the same dosage and pharmaceutical form as the reference drugs, but by law are sold at at least a 35% discount. They are produced after the patent of a pioneering drug has expired, allowing other manufacturers to make equivalent versions.
Their quality, safety and efficacy are strictly regulated by health agencies around the world. In Brazil, the National Health Surveillance Agency(Anvisa) assesses a series of technical criteria, one of which is that generics must demonstrate bioequivalence, i.e. that they must be absorbed by the body at the same rate and in the same quantity.
The success of generic drugs, which have been available in pharmacies since 2001, is credited to Law 9.787, which not only introduced the concept of generics, but also established regulations for the category of drugs in Brazil.
Check it out in full: Generic Medicines Law: Law No. 9.787, of February 10, 1999.
Their quality, safety and efficacy are strictly regulated by health agencies around the world. In Brazil, the National Health Surveillance Agency(Anvisa) assesses a series of technical criteria, one of which is that generics must demonstrate bioequivalence, i.e. that they must be absorbed by the body at the same rate and in the same quantity.
The success of generic drugs, which have been available in pharmacies since 2001, is credited to Law 9.787, which not only introduced the concept of generics, but also established regulations for the category of drugs in Brazil.
Check it out in full: Generic Medicines Law: Law No. 9.787, of February 10, 1999.
What are
GENERIC MEDICINES
Generics are drugs that contain the same active ingredients, in the same dosage and pharmaceutical form as the reference drugs, but by law are sold at at least a 35% discount. They are produced after the patent of a pioneering drug has expired, allowing other manufacturers to make equivalent versions.
Their quality, safety and efficacy are strictly regulated by health agencies around the world. In Brazil, the National Health Surveillance Agency(Anvisa) assesses a series of technical criteria, one of which is that generics must demonstrate bioequivalence, i.e. that they must be absorbed by the body at the same rate and in the same quantity.
The success of generic drugs, which have been available in pharmacies since 2001, is credited to Law 9.787, which not only introduced the concept of generics, but also established regulations for the category of drugs in Brazil.
Check it out in full: Generic Medicines Law: Law No. 9.787, of February 10, 1999.
Their quality, safety and efficacy are strictly regulated by health agencies around the world. In Brazil, the National Health Surveillance Agency(Anvisa) assesses a series of technical criteria, one of which is that generics must demonstrate bioequivalence, i.e. that they must be absorbed by the body at the same rate and in the same quantity.
The success of generic drugs, which have been available in pharmacies since 2001, is credited to Law 9.787, which not only introduced the concept of generics, but also established regulations for the category of drugs in Brazil.
Check it out in full: Generic Medicines Law: Law No. 9.787, of February 10, 1999.
Benefits of
GENERICS
Our members include the companies at the top of the generics and biosimilars market in Brazil and globally.
Market in Brazil
Market Leadership
Brazil has a prominent position in the global pharmaceutical market, being considered the 7th LARGEST PHARMACEUTICAL MARKET in the world and the largest in Latin America.
0
bi
Faturamento 2025 (R$/Bilhões)
0
%
Crescimento anual em relação a 2024
(vs. 11,63% do mercado total)
0
%
Cumulative growth (last 5 years)
Prescription and Access
medicines
most prescribed in Brazil are generics
of known diseases
already have generic drugs
medicines
of the Popular Pharmacy Program are generic
is the percentage of sales
of generics in Brazil
is the average discount
of a generic drug
consumers
feel a high degree of trust
JOB CREATION
DIRECT JOBS
91 thousand
INDIRECT JOBS
800 thousand
professionals with higher education or more
43%
female workforce
50%
Public-Private Partnership
More than 14 billion units dispensed annually
Federal investment in 2023: R$2.6 billion
Market projections until 2030
Estimated savings for the population
By 2028, the accumulated savings for the population should exceed R$ 500 billion, representing more than R$ 4 billion per month in the economy.
By 2030, the total saved should
exceed R$ 632 billion.
exceed R$ 632 billion.
Estimated economy Population
The projection for the coming years shows consistent growth:
Volume of
PRODUCTION
The production of generic medicines in the country is also continuing apace:
On average, more than 2.5 billion boxes per year.
Between 2020 and 2025, more than 11 billion boxes of generic medicines sold. It is estimated that, by 2030, the industry will sell another 14 billion boxes, totaling more than 25 billion units manufactured over the decade.
Between 2020 and 2025, more than 11 billion boxes of generic medicines sold. It is estimated that, by 2030, the industry will sell another 14 billion boxes, totaling more than 25 billion units manufactured over the decade.
Market Share Growth
The projection for the coming years shows consistent growth, with emphasis on:
2025
40.03%
2026
40.71%
2027
41.77%
2028
42.86%
2029
43.97%
2030
45.12%
This represents a growth of more than 5 percentage points in 5 years.
Summary
Generics should generate savings of more than R$ 632 billion by 2030.
Cumulative sales should exceed 25 billion boxes over the decade.
Market share should reach 45.12% by 2030, with growth of 1.09% percentage points per year.
Source: PróGenéricos / IQVIA
Market share should reach 45.12% by 2030, with growth of 1.09% percentage points per year.
Source: PróGenéricos / IQVIA